EV Biotech
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
EV Biotech was a Dutch biotechnology company based in Groningen, founded in 2018 by Linda Dijkshoorn. It specialized in microbial cell factory strain development: building computational models of bacterial strains to design and optimize precision fermentation for producing chemical compounds for flavors and fragrances, biomaterials, agriculture, and pharmaceutical markets. The company initially operated as a contract research organization before pivoting toward strategic partnerships.
02 / EV Biotech FAILURE REASONS
Failure factors
Customers withdrew and remaining revenue could not sustain operations. Investors were unwilling to contribute additional capital.
03 / EVENT HISTORY
Events in the structured record
- Bankruptcy
EV Biotech was declared bankrupt on 3 December 2024.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Raised a 4.5 million EUR seed round in March 2023 led by Future Food Fund, with Blue Horizon, NOM, Carduso Capital, RUG Ventures, and others (about $4.9 million).
- 02
Filed for bankruptcy in 2024 after running out of runway.
- 03
Made a fresh start under new ownership of RUG Ventures in March 2025, with additional investment, new leadership, and a refined strategy focused on strategic partnerships instead of contract research.